サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1370943

子宮筋腫治療薬市場- 世界の産業規模、シェア、動向、機会、予測、2018～2028年、薬剤クラス別、タイプ別、エンドユーザー別、地域別、競合

Uterine Fibroid Treatment Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Drug Class, By Type, By End User, By Region, Competition
出版日: | 発行: TechSci Research | ページ情報: 英文 171 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円

こちらのレポートには、数時間（ご購入金額の10%）分のアナリストへの質問／追加調査サービスが含まれております。

子宮筋腫治療薬市場- 世界の産業規模、シェア、動向、機会、予測、2018～2028年、薬剤クラス別、タイプ別、エンドユーザー別、地域別、競合
出版日: 2023年10月03日
発行: TechSci Research
ページ情報: 英文 171 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 目次
概要

子宮筋腫治療薬の世界市場は、2022年に44億2,000万米ドルの評価額に達し、予測期間には大幅な成長が見込まれており、予想年間平均成長率（CAGR）は4.43%で、2028年までには57億1,000万米ドルに達する見込みです。

この成長の原動力となっているのは、市場情勢を再構築しているいくつかの重要な要因です。

主な市場促進要因

1.子宮筋腫の有病率の増加

市場概要
予測期間 2024～2028年
2022年の市場規模 44億2,000万米ドル
2028年の市場規模 57億1,000万米ドル
CAGR 2023～2028年 4.43%
急成長セグメント ゴナジトロピン放出ホルモン作動薬
最大市場 北米

子宮筋腫は子宮内で成長する良性腫瘍であり、女性にとって世界の健康上の重要な関心事となっています。子宮筋腫の有病率は増加傾向にあり、医療専門家、研究者、政策立案者はその要因を理解する必要に迫られています。子宮筋腫は平滑筋腫としても知られ、子宮の筋肉組織に発生する非がん性の増殖です。子宮筋腫は特に生殖期に多く、月経多量出血、骨盤痛、隣接臓器の圧迫などの症状を引き起こすことがあります。ここ数十年、子宮筋腫の有病率は世界中で着実に増加しています。この動向は、ライフスタイルの変化、食習慣、身体活動レベル、出産の遅れ、ホルモンの変動、遺伝的要因など、さまざまな要因が複雑に絡み合って引き起こされています。この増加の背景を理解することは、増大する子宮筋腫の負担に対処し、効果的な治療法を開発する上で極めて重要です。

2.治療パラダイムの転換

子宮筋腫の治療は、歴史的に子宮摘出術や子宮筋腫核出術といった伝統的な外科的治療が中心でした。しかし、革新的な薬物療法が注目されるにつれ、治療パラダイムに顕著な変化が生じています。この変化の背景には、生殖能力を維持し、回復が早く、手術に伴うリスクを最小限に抑えた、侵襲の少ない治療法を求める声があります。子宮筋腫治療薬は、医薬品療法としても知られ、手術に代わる実行可能な選択肢として登場しました。これらの薬剤は、子宮筋腫の成長に影響を与えるホルモンを調整することで作用し、症状を軽減し、侵襲的な処置の必要性を減少させる。治療アプローチのこの変革は、患者の転帰を改善し、子宮筋腫に対処する女性が利用できる選択肢の幅を広げています。

3.有利な規制環境

規制状況は、新しい治療法の入手可能性と利用しやすさを形成する上で極めて重要な役割を果たしています。子宮筋腫治療薬市場は、技術革新と新規治療法のイントロダクションを奨励する有利な規制環境の恩恵を受けています。規制機関は、女性の健康に大きな影響を与える子宮筋腫のような疾患を優先しています。アンメット・メディカル・ニーズに対応する医薬品には迅速な審査パスが付与され、開発・承認プロセスのスピードアップが図られています。また、子宮筋腫に対する認識を高め、治療法の改善を提唱する上で、女性の健康を専門とする患者支援団体や組織も重要な役割を果たしています。このような良好な規制環境は、革新的な治療法へのタイムリーなアクセスを提供することで患者に利益をもたらすだけでなく、製薬企業の研究開発への投資意欲を高めることにもつながっています。

主な市場課題

1.有効性と長期データ

子宮筋腫治療薬は症状の緩和において有望であるが、長期的な有効性と安全性については疑問が残る。臨床試験の観察期間は比較的短いことが多く、これらの薬剤の長期的な効果を完全に理解することは困難です。確実な長期データを作成することは、患者の幸福とこれらの治療に対する信頼を確保するために極めて重要です。

2.患者のばらつき

子宮筋腫は、大きさ、部位、患者プロファイルの点でかなりのばらつきを示します。この不均一性を効果的に標的とする薬剤の開発は重要な課題です。個別化医療（personalized medicine）のアプローチは普及しつつあるが、個々の患者に合わせた治療法は依然として複雑であり、精密医療（precision medicine）のさらなる進歩が必要であろう。

3.副作用と忍容性

他の医療介入と同様に、子宮筋腫治療薬にも副作用があります。症状の緩和と潜在的な副作用のバランスをとることは微妙な仕事です。過度の不快感を与えることなく有意義な利益をもたらす適切なバランスを達成することは、患者の受容とアドヒアランスにとって不可欠です。

主な市場動向

1.併用療法

子宮筋腫治療薬と低侵襲手術やホルモン療法などの他の治療法との併用は、非常に有望です。これらの相乗的なアプローチは、子宮筋腫を多角的に対象とする包括的なソリューションを提供し、症状の緩和と長期的な転帰を最適化することを目的としています。併用療法は、さまざまな子宮筋腫の特徴を持つ患者に合わせた治療を提供し、治療の全体的な有効性を高めることができます。

2.QOLの重視

今後の動向は、医学的な有効性だけでなく、患者のQOLの向上に重点を置く。症状を緩和するだけでなく、全体的な幸福感を向上させる子宮筋腫治療薬が最前線に登場すると思われます。製薬会社は、子宮筋腫が生活の身体的、感情的、社会的側面に与える全人的な影響を認識し、より広範な患者のニーズに対応する治療法を模索しています。

3.非ホルモン療法の選択肢

子宮筋腫治療ではホルモン療法が主流であったが、非ホルモン療法の選択肢も増えつつあります。ホルモンレベルに影響を与えることなく、子宮筋腫の成長に関与する特定の細胞経路を標的とする新薬が研究されています。このような非ホルモン治療は、ホルモン治療が適さない患者にとって選択肢となる可能性があります。

セグメント別洞察

タイプ別洞察

2022年には、粘膜下筋腫が世界の子宮筋腫治療薬市場を独占しました。粘膜下筋腫は良性の子宮増殖症で、生殖期に発現することが多いです。しかし、2023年から2030年にかけては、硬膜内筋腫のカテゴリーが最も高い複合年間成長率（CAGR）を示すと予想されています。硬膜内筋腫

エンドユーザー別洞察

小売薬局セグメントは2022年に市場を独占し、今後も拡大が続くと予想されます。小売薬局は、市販の鎮痛薬、経口治療薬、GnRH拮抗薬など、子宮筋腫治療に使用される医薬品を広く提供しています。このセグメントの成長は、患者の間で安全で効率的な治療の選択肢が求められていることが背景にあります。

地域別洞察

北米は、子宮筋腫の有病率の上昇、子宮筋腫による妊娠合併症、新しい治療オプションの承認により、世界の子宮筋腫治療薬市場をリードしています。この地域の医療事情は子宮筋腫の高い発生率にも影響されており、50歳までに黒人女性の最大80%、白人女性の最大70%が子宮筋腫を経験しています。子宮筋腫に対する認識の高まりと治療オプションの拡大は、北米における市場のさらなる成長を促進すると予想されます。

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 臨床試験分析

第6章 子宮筋腫治療薬の世界市場展望

  • 市場規模・予測
    • 金額別
  • 市場シェアと予測
    • 薬剤クラス別（ゴナドトロピン放出ホルモン（Gnrh）アゴニスト、ゴナドトロピン放出ホルモン（Gnrh）アンタゴニスト、黄体ホルモン放出子宮内避妊薬、非ホルモン薬、その他）
    • タイプ別（漿膜下子宮筋腫、硬膜内子宮筋腫、粘膜下子宮筋腫、血腫型子宮筋腫）
    • エンドユーザー別（病院薬局、小売薬局、その他）
    • 地域別
    • 企業別（2022年）
  • 製品市場マップ
    • 薬剤クラス別
    • タイプ別
    • エンドユーザー別
    • 地域別

第7章 北米の子宮筋腫治療薬市場展望

  • 市場規模および予測
    • 金額別
  • 市場シェアと予測
    • 薬剤クラス別
    • タイプ別
    • エンドユーザー別
    • 国別
  • 北米：国別分析
    • 米国
    • メキシコ
    • カナダ

第8章 欧州の子宮筋腫治療薬市場展望

  • 市場規模・予測
    • 金額別
  • 市場シェアと予測
    • 薬剤クラス別
    • タイプ別
    • エンドユーザー別
    • 国別
  • 欧州：国別分析
    • フランス
    • ドイツ
    • 英国
    • イタリア
    • スペイン

第9章 アジア太平洋の子宮筋腫治療薬市場展望

  • 市場規模・予測
    • 金額別
  • 市場シェアと予測
    • 薬剤クラス別
    • タイプ別
    • エンドユーザー別
    • 国別
  • アジア太平洋：国別分析
    • 中国
    • インド
    • 韓国
    • 日本
    • オーストラリア

第10章 南米の子宮筋腫治療薬市場展望

  • 市場規模・予測
    • 金額別
  • 市場シェアと予測
    • 薬剤クラス別
    • タイプ別
    • エンドユーザー別
    • 国別
  • 南米：国別分析
    • ブラジル
    • アルゼンチン
    • コロンビア

第11章 中東・アフリカの子宮筋腫治療薬市場展望

  • 市場規模および予測
    • 金額別
  • 市場シェアと予測
    • 薬剤クラス別
    • タイプ別
    • エンドユーザー別
    • 国別
  • 中東・アフリカ：国別分析
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • クウェート

第12章 市場力学

  • 促進要因
  • 課題

第13章 市場動向と発展

  • 製品上市
  • 合併・買収

第14章 政策・規制状況

第15章 ポーターのファイブフォース分析

  • 業界内の競合
  • 新規参入の可能性
  • サプライヤーの力
  • 顧客の力
  • 代替品の脅威

第16章 競合情勢

  • Myovant Sciences Ltd
  • Pfizer Inc
  • Abbvie Inc
  • Ferring BV
  • AstraZeneca Pharmaceuticals LP
  • Bayer AG
  • Amring Pharmaceuticals Inc
  • Watson Pharma Pvt Ltd

第17章 戦略的提言

第18章 調査会社について・免責事項

目次
Product Code: 17232

The Global Uterine Fibroid Treatment Drugs Market reached a valuation of USD 4.42 Billion in 2022 and is poised for substantial growth in the forecast period, with a projected Compound Annual Growth Rate (CAGR) of 4.43% and expected to reach USD 5.71 Billion through 2028. This growth is driven by several key factors reshaping the market landscape.

Key Market Drivers

1. Increasing Prevalence of Uterine Fibroids

Market Overview
Forecast Period2024-2028
Market Size 2022USD 4.42 Billion
Market Size 2028USD 5.71 Billion
CAGR 2023-20284.43%
Fastest Growing SegmentGonaditropin releasing hormone ag0nists
Largest MarketNorth America

Uterine fibroids, which are benign tumors growing in the uterus, have become a significant global health concern for women. The prevalence of uterine fibroids is on the rise, prompting healthcare professionals, researchers, and policymakers to understand the contributing factors. Uterine fibroids, also known as leiomyomas, are non-cancerous growths that develop in the muscle tissue of the uterus. They are particularly common during the reproductive years and can cause symptoms like heavy menstrual bleeding, pelvic pain, and pressure on adjacent organs. In recent decades, the prevalence of uterine fibroids has steadily increased worldwide. This trend is driven by a complex interplay of factors, including changes in lifestyle, dietary habits, physical activity levels, delayed childbirth, hormonal fluctuations, and genetic factors. Understanding the reasons behind this increase is crucial for addressing the growing burden of uterine fibroids and developing effective treatment options.

2. Shifting Treatment Paradigms

Traditional surgical interventions such as hysterectomy and myomectomy have historically been the primary treatments for uterine fibroids. However, there is a notable shift in treatment paradigms as innovative pharmaceutical therapies gain prominence. This shift is driven by the desire for less invasive treatment options that preserve fertility, offer quicker recovery times, and minimize risks associated with surgery. Uterine fibroid treatment drugs, also known as pharmaceutical therapies, have emerged as viable alternatives to surgery. These drugs work by regulating hormones that influence fibroid growth, reducing symptoms, and decreasing the need for invasive procedures. This transformation in treatment approaches is improving patient outcomes and expanding the range of options available to women dealing with uterine fibroids.

3. Favorable Regulatory Environment

The regulatory landscape plays a pivotal role in shaping the availability and accessibility of new medical treatments. The uterine fibroid treatment drugs market benefits from a favorable regulatory environment that encourages innovation and the introduction of novel therapies. Regulatory agencies prioritize conditions like uterine fibroids, which have a significant impact on women's health. Expedited review pathways are granted to drugs addressing unmet medical needs, speeding up their development and approval processes. Patient advocacy groups and organizations dedicated to women's health have also played a crucial role in raising awareness about uterine fibroids and advocating for improved treatment options. This favorable regulatory environment not only benefits patients by providing timely access to innovative therapies but also incentivizes pharmaceutical companies to invest in research and development.

Key Market Challenges

1. Efficacy and Long-Term Data

While uterine fibroid treatment drugs show promise in alleviating symptoms, questions about their long-term efficacy and safety persist. Clinical trials often have relatively short observation periods, making it challenging to fully understand the long-term effects of these drugs. Generating robust long-term data is crucial to ensure patient well-being and confidence in these treatments.

2. Patient Variability

Uterine fibroids exhibit considerable variability in terms of size, location, and patient profiles. Developing drugs that effectively target this heterogeneity is a significant challenge. Personalized medicine approaches are gaining traction, but tailoring treatments to individual patients remains complex and may require further advancements in precision medicine.

3. Side Effects and Tolerability

Like any medical intervention, uterine fibroid treatment drugs can have side effects. Balancing symptom relief with potential adverse effects is a delicate task. Achieving the right balance to provide meaningful benefits without causing undue discomfort is essential for patient acceptance and adherence.

Key Market Trends

1. Combination Therapies

Combining uterine fibroid treatment drugs with other interventions, such as minimally invasive procedures or hormonal therapies, holds immense promise. These synergistic approaches aim to provide comprehensive solutions that target fibroids from multiple angles, optimizing symptom relief and long-term outcomes. Combination therapies can offer tailored treatments for patients with varying fibroid characteristics, enhancing the overall effectiveness of care.

2. Focus on Quality of Life

Beyond medical efficacy, future trends emphasize enhancing patients' quality of life. Uterine fibroid treatment drugs that not only alleviate symptoms but also improve overall well-being will be at the forefront. Pharmaceutical companies are exploring therapies that address a broader spectrum of patient needs, acknowledging the holistic impact of uterine fibroids on physical, emotional, and social aspects of life.

3. Non-Hormonal Treatment Options

While hormonal therapies have been a mainstay in uterine fibroid treatment, non-hormonal options are gaining traction. New drugs that target specific cellular pathways involved in fibroid growth, without affecting hormone levels, are being explored. These non-hormonal treatments may offer alternatives for patients who are not suitable candidates for hormonal interventions.

Segmental Insights

Type Insights

In 2022, submucosal fibroids dominated the global uterine fibroid treatment drugs market. Submucosal fibroids are benign uterine growths that often manifest during reproductive years. However, the intramural fibroids category is expected to experience the highest compound annual growth rate (CAGR) from 2023 to 2030. Intramural fibroids

are known to drastically affect fertility outcomes, making their treatment a priority.

End User Industry Insights

The retail pharmacies segment dominated the market in 2022 and is expected to continue expanding. Retail pharmacies offer widespread availability of pharmaceuticals used in uterine fibroid treatment, including over-the-counter pain drugs, oral treatments, and GnRH antagonists. This segment's growth is driven by the demand for safe and efficient treatment choices among patients.

Regional Insights

North America leads the global uterine fibroid treatment drugs market due to the rising prevalence of fibroids, pregnancy complications caused by fibroids, and the approval of new treatment options. The region's healthcare landscape is also influenced by the high incidence of fibroids, with up to 80% of Black women and up to 70% of White women experiencing fibroids by the age of 50. The increasing awareness of fibroids and expanding treatment options are expected to fuel further market growth in North America.

Key Market Players

  • Myovant Sciences Ltd
  • Pfizer Inc
  • Abbvie Inc
  • Ferring BV
  • AstraZeneca Pharmaceuticals LP
  • Bayer AG
  • Amring Pharmaceuticals Inc
  • Watson Pharma Pvt Ltd

Report Scope:

In this report, the Global Uterine Fibroid Treatment Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below.

Uterine Fibroid Treatment Drugs Market, By Drug Class:

  • Gonadotropin-Releasing Hormone (Gnrh) Agonists
  • Gonadotropin-Releasing Hormone (Gnrh) Antagonists
  • Progestin-Releasing Intrauterine Device (Iud) & Contraceptives
  • Non-Hormonal Medications
  • Others

Uterine Fibroid Treatment Drugs Market, By Type:

  • Subserosal Fibroids
  • Intramural Fibroids
  • Submucosal Fibroids
  • Pedunculated Fibroids

Uterine Fibroid Treatment Drugs Market, By End User:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Others

Uterine Fibroid Treatment Drugs Market, By region:

  • North America
  • United States
  • Mexico
  • Canada
  • Europe
  • France
  • Germany
  • United Kingdom
  • Italy
  • Spain
  • Asia-Pacific
  • China
  • India
  • South Korea
  • Japan
  • Australia
  • South America
  • Brazil
  • Argentina
  • Colombia
  • Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Competitive Landscape

  • Company Profiles: Detailed analysis of the major companies present in the Global Uterine Fibroid Treatment Drugs Market.

Available Customizations:

  • Global Uterine Fibroid Treatment Drugs Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Clinical Trial Analysis

  • 5.1. Ongoing Clinical Trials
  • 5.2. Completed Clinical Trials
  • 5.3. Terminated Clinical Trials
  • 5.4. Breakdown of Pipeline, By Development Phase
  • 5.5. Breakdown of Pipeline, By Status
  • 5.6. Breakdown of Pipeline, By Study Application
  • 5.7. Breakdown of Pipeline, By Region
  • 5.8. Clinical Trials Heat Map

6. Global Uterine Fibroid Treatment Drugs Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Drug Class (Gonadotropin-Releasing Hormone (Gnrh) Agonists, Gonadotropin-Releasing Hormone (Gnrh) Antagonists, Progestin-Releasing Intrauterine Device (Iud) & Contraceptives, Non-Hormonal Medications, Others)
    • 6.2.2. By Type (Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids, Pedunculated Fibroids)
    • 6.2.3. By End User (Hospital Pharmacies, Retail Pharmacies, Others)
    • 6.2.4. By Region
    • 6.2.5. By Company (2022)
  • 6.3. Product Market Map
    • 6.3.1. By Drug Class
    • 6.3.2. By Type
    • 6.3.3. By End User
    • 6.3.4. By Region

7. North America Uterine Fibroid Treatment Drugs Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Drug Class (Gonadotropin-Releasing Hormone (Gnrh) Agonists, Gonadotropin-Releasing Hormone (Gnrh) Antagonists, Progestin-Releasing Intrauterine Device (Iud) & Contraceptives, Non-Hormonal Medications, Others)
    • 7.2.2. By Type (Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids, Pedunculated Fibroids)
    • 7.2.3. By End User (Hospital Pharmacies, Retail Pharmacies, Others)
    • 7.2.4. By Country
  • 7.3. North America: Country Analysis
    • 7.3.1. United States Uterine Fibroid Treatment Drugs Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Drug Class
        • 7.3.1.2.2. By Type
        • 7.3.1.2.3. By End User
    • 7.3.2. Mexico Uterine Fibroid Treatment Drugs Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Drug Class
        • 7.3.2.2.2. By Type
        • 7.3.2.2.3. By End User
    • 7.3.3. Canada Uterine Fibroid Treatment Drugs Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Drug Class
        • 7.3.3.2.2. By Type
        • 7.3.3.2.3. By End User

8. Europe Uterine Fibroid Treatment Drugs Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Drug Class (Gonadotropin-Releasing Hormone (Gnrh) Agonists, Gonadotropin-Releasing Hormone (Gnrh) Antagonists, Progestin-Releasing Intrauterine Device (Iud) & Contraceptives, Non-Hormonal Medications, Others)
    • 8.2.2. By Type (Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids, Pedunculated Fibroids)
    • 8.2.3. By End User (Hospital Pharmacies, Retail Pharmacies, Others)
    • 8.2.4. By Country
  • 8.3. Europe: Country Analysis
    • 8.3.1. France Uterine Fibroid Treatment Drugs Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Drug Class
        • 8.3.1.2.2. By Type
        • 8.3.1.2.3. By End User
    • 8.3.2. Germany Uterine Fibroid Treatment Drugs Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Drug Class
        • 8.3.2.2.2. By Type
        • 8.3.2.2.3. By End User
    • 8.3.3. United Kingdom Uterine Fibroid Treatment Drugs Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Drug Class
        • 8.3.3.2.2. By Type
        • 8.3.3.2.3. By End User
    • 8.3.4. Italy Uterine Fibroid Treatment Drugs Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Drug Class
        • 8.3.4.2.2. By Type
        • 8.3.4.2.3. By End User
    • 8.3.5. Spain Uterine Fibroid Treatment Drugs Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Drug Class
        • 8.3.5.2.2. By Type
        • 8.3.5.2.3. By End User

9. Asia-Pacific Uterine Fibroid Treatment Drugs Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Drug Class (Gonadotropin-Releasing Hormone (Gnrh) Agonists, Gonadotropin-Releasing Hormone (Gnrh) Antagonists, Progestin-Releasing Intrauterine Device (Iud) & Contraceptives, Non-Hormonal Medications, Others)
    • 9.2.2. By Type (Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids, Pedunculated Fibroids)
    • 9.2.3. By End User (Hospital Pharmacies, Retail Pharmacies, Others)
    • 9.2.4. By Country
  • 9.3. Asia-Pacific: Country Analysis
    • 9.3.1. China Uterine Fibroid Treatment Drugs Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Drug Class
        • 9.3.1.2.2. By Type
        • 9.3.1.2.3. By End User
    • 9.3.2. India Uterine Fibroid Treatment Drugs Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Drug Class
        • 9.3.2.2.2. By Type
        • 9.3.2.2.3. By End User
    • 9.3.3. South Korea Uterine Fibroid Treatment Drugs Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Drug Class
        • 9.3.3.2.2. By Type
        • 9.3.3.2.3. By End User
    • 9.3.4. Japan Uterine Fibroid Treatment Drugs Market Outlook
      • 9.3.4.1. Market Size & Forecast
        • 9.3.4.1.1. By Value
      • 9.3.4.2. Market Share & Forecast
        • 9.3.4.2.1. By Drug Class
        • 9.3.4.2.2. By Type
        • 9.3.4.2.3. By End User
    • 9.3.5. Australia Uterine Fibroid Treatment Drugs Market Outlook
      • 9.3.5.1. Market Size & Forecast
        • 9.3.5.1.1. By Value
      • 9.3.5.2. Market Share & Forecast
        • 9.3.5.2.1. By Drug Class
        • 9.3.5.2.2. By Type
        • 9.3.5.2.3. By End User

10. South America Uterine Fibroid Treatment Drugs Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Drug Class (Gonadotropin-Releasing Hormone (Gnrh) Agonists, Gonadotropin-Releasing Hormone (Gnrh) Antagonists, Progestin-Releasing Intrauterine Device (Iud) & Contraceptives, Non-Hormonal Medications, Others)
    • 10.2.2. By Type (Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids, Pedunculated Fibroids)
    • 10.2.3. By End User (Hospital Pharmacies, Retail Pharmacies, Others)
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Uterine Fibroid Treatment Drugs Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Drug Class
        • 10.3.1.2.2. By Type
        • 10.3.1.2.3. By End User
    • 10.3.2. Argentina Uterine Fibroid Treatment Drugs Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Drug Class
        • 10.3.2.2.2. By Type
        • 10.3.2.2.3. By End User
    • 10.3.3. Colombia Uterine Fibroid Treatment Drugs Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Drug Class
        • 10.3.3.2.2. By Type
        • 10.3.3.2.3. By End User

11. Middle East and Africa Uterine Fibroid Treatment Drugs Market Outlook

  • 11.1. Market Size & Forecast
    • 11.1.1. By Value
  • 11.2. Market Share & Forecast
    • 11.2.1. By Drug Class (Gonadotropin-Releasing Hormone (Gnrh) Agonists, Gonadotropin-Releasing Hormone (Gnrh) Antagonists, Progestin-Releasing Intrauterine Device (Iud) & Contraceptives, Non-Hormonal Medications, Others)
    • 11.2.2. By Type (Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids, Pedunculated Fibroids)
    • 11.2.3. By End User (Hospital Pharmacies, Retail Pharmacies, Others)
    • 11.2.4. By Country
  • 11.3. MEA: Country Analysis
    • 11.3.1. South Africa Uterine Fibroid Treatment Drugs Market Outlook
      • 11.3.1.1. Market Size & Forecast
        • 11.3.1.1.1. By Value
      • 11.3.1.2. Market Share & Forecast
        • 11.3.1.2.1. By Drug Class
        • 11.3.1.2.2. By Type
        • 11.3.1.2.3. By End User
    • 11.3.2. Saudi Arabia Uterine Fibroid Treatment Drugs Market Outlook
      • 11.3.2.1. Market Size & Forecast
        • 11.3.2.1.1. By Value
      • 11.3.2.2. Market Share & Forecast
        • 11.3.2.2.1. By Drug Class
        • 11.3.2.2.2. By Type
        • 11.3.2.2.3. By End User
    • 11.3.3. UAE Uterine Fibroid Treatment Drugs Market Outlook
      • 11.3.3.1. Market Size & Forecast
        • 11.3.3.1.1. By Value
      • 11.3.3.2. Market Share & Forecast
        • 11.3.3.2.1. By Drug Class
        • 11.3.3.2.2. By Type
        • 11.3.3.2.3. By End User
    • 11.3.4. Kuwait Uterine Fibroid Treatment Drugs Market Outlook
      • 11.3.4.1. Market Size & Forecast
        • 11.3.4.1.1. By Value
      • 11.3.4.2. Market Share & Forecast
        • 11.3.4.2.1. By Drug Class
        • 11.3.4.2.2. By Type
        • 11.3.4.2.3. By End User

12. Market Dynamics

  • 12.1. Drivers
  • 12.2. Challenges

13. Market Trends & Developments

  • 13.1. Recent Developments
  • 13.2. Product Launches
  • 13.3. Mergers & Acquisitions

14. Policy & Regulatory Landscape

15. Porter's Five Forces Analysis

  • 15.1. Competition in the Industry
  • 15.2. Potential of New Entrants
  • 15.3. Power of Suppliers
  • 15.4. Power of Customers
  • 15.5. Threat of Substitute Product

16. Competitive Landscape

  • 16.1. Business Overview
  • 16.2. Company Snapshot
  • 16.3. Products & Services
  • 16.4. Financials (In case of listed companies)
  • 16.5. Recent Developments
  • 16.6. SWOT Analysis
    • 16.6.1. Myovant Sciences Ltd
    • 16.6.2. Pfizer Inc
    • 16.6.3. Abbvie Inc
    • 16.6.4. Ferring BV
    • 16.6.5. AstraZeneca Pharmaceuticals LP
    • 16.6.6. Bayer AG
    • 16.6.7. Amring Pharmaceuticals Inc
    • 16.6.8. Watson Pharma Pvt Ltd

17. Strategic Recommendations

18. About Us & Disclaimer